Latest Cornerstone Therapeutics Inc (CRTX) Headlin
Post# of 24
Posted On: 03/13/2014 7:10:05 AM
Latest Cornerstone Therapeutics Inc (CRTX) Headlines
Healthfirst Improves Member Retention Using Decision Point's "Micro Targeting" Technology
Business Wire - Tue Feb 25, 6:00AM CST
Decision Point Healthcare Solutions (Decision Point), an innovator in providing engagement analytics solutions to the health care industry, announced today that Healthfirst -- a not-for-profit managed care organization offering a variety of low- or no-cost health insurance programs to qualified individuals and families living in the New York metropolitan area -- was able to significantly improve Medicare member retention through its Decision Point-powered program to continually enhance its members' plan experience.
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Chiesi Farmaceutici Completes Acquisition of Cornerstone Therapeutics
PR Newswire - Tue Feb 04, 6:00AM CST
Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced that Chiesi has acquired all of the outstanding common shares of Cornerstone not already owned by Chiesi for $9.50 per share in cash. Prior to completing the transaction, Chiesi owned 58% of Cornerstone's outstanding shares.
Cornerstone Therapeutics Inc's stockholders votes in favour of merger with Chiesi Farmaceutici SpA at USD9.50 per share
M2 - Tue Feb 04, 4:38AM CST
Cornerstone Therapeutics Inc (NASDAQ:CRTX) stated on Monday that all of its outstanding common shares will be acquired for USD9.50 per share in cash under an approved merger agreement with Chiesi Farmaceutici SpA (Chiesi).
Cornerstone Therapeutics Inc. Stockholders Approve Merger
Marketwire - Mon Feb 03, 1:25PM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the "Company" or "Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, today announced that its stockholders have approved, at a special stockholder meeting held today, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. ("Chiesi") will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.
Cornerstone Therapeutics Adjourns Special Meeting of Stockholders
Marketwire - Fri Jan 31, 5:57PM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone") today announced that the special meeting of its stockholders scheduled to take place today has been adjourned. The special meeting will resume on February 3, 2014, at 1 p.m. EST at Cornerstone's offices located at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518. The purpose of the adjournment is to complete the solicitation of votes required for approval of a merger between Cornerstone and a subsidiary of Cornerstone's majority shareholder, Chiesi Farmaceutici S.p.A ("Chiesi").
Drugmaker Aptalis Files For IPO After Overhaul
at Investor's Business Daily - Thu Dec 26, 10:50AM CST
Drugmaker Aptalis Holdings filed to go public Thursday in an IPO expected to raise around half a billion dollars, as the company formerly traded as Axcan Pharma returns in a new incarnation. Private-equity firm TPG Capital acquired Axcan in 2007 and...
Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
Marketwire - Wed Nov 20, 7:02AM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today the launch of BETHKIS(R) (Tobramycin Inhalation Solution), a nebulized therapy indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.(1)
ACAD, CRTX, MACK and NVAX added to NASDAQ Healthcare Stock Watch List at EPR
ACCESSWIRE - Thu Nov 07, 8:28AM CST
New York, NY - (ACCESSWIRE) - 11/07/2013 - Equity Profile Report initiates its Health-care Stock Watch List adding ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), and Novavax, Inc. (NASDAQ:NVAX)
Cornerstone Therapeutics Reports Third Quarter 2013 Financial Results
Marketwire - Thu Nov 07, 6:01AM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call
Marketwire - Thu Oct 31, 4:01PM CDT
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, November 7, 2013, to discuss its financial results for the third quarter of 2013 ended September 30, 2013. Financial results are expected to be released before the open of the U.S. financial markets on Thursday, November 7, 2013.
Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
PR Newswire - Fri Oct 18, 1:25PM CDT
Securities lawyers at Deans & Lyons announced a class action against the board of Cornerstone Therapeutics Inc. (NASDAQ: CRTX) in connection with a buyout for $9.50 per share. Concerned CRTX investors should contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American Cystic Fibrosis Conference
Marketwire - Thu Oct 17, 8:02AM CDT
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) will exhibit at the North American Cystic Fibrosis Conference (NACFC), Oct. 17-19 at the Salt Palace Convention Center in Salt Lake City. The annual scientific meeting, sponsored by the Cystic Fibrosis Foundation, is designed for medical professionals focused on CF research and patient care.
Osiris Shares Continue to Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 15, 9:30AM CDT
Shares are up on the company's agreement for the sale of its culture-expanded mesenchymal stem cell business.
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Cornerstone Therapeutics, Inc. Buyout
Business Wire - Thu Sep 19, 2:44PM CDT
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Cornerstone Therapeutics, Inc.
Business Wire - Wed Sep 18, 8:00PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cornerstone Therapeutics, Inc. ("Cornerstone" or the "Company") (Nasdaq: CRTX) relating to the proposed acquisition by Chiesi Farmaceutici S.P.A. ("Chiesi").
Downgrade Alert for Cornerstone Therapeutics (CRTX)
Comtex SmarTrend(R) - Wed Sep 18, 7:11AM CDT
Cornerstone Therapeutics (NASDAQ:CRTX) was downgraded from Buy to Neutral at Ladenburg today. The stock closed yesterday at $9.40 on volume of 457,000 shares, above average daily volume of 83,000. Cornerstone Therapeutics share prices have moved between a 52-week high of $10.37 and a 52-week low of $4.56 and closed yesterday at 106% above that low price at $9.40 per share. Over the past week, the 200-day moving average (MA) has gone up 0.9% while the 50-day MA has advanced 0.9%.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by Board of Cornerstone Therapeutics, Inc. In Connection With Sale Of Company to Chiesi Farmaceutici SpA
PR Newswire - Tue Sep 17, 2:41PM CDT
Levi & Korsinsky is investigating the Board of Directors of Cornerstone Therapeutics, Inc. ("Cornerstone" or the "Company") (Nasdaq: CRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Chiesi Farmaceutici SpA ("Chiesi").
Ryan & Maniskas, LLP Announces Investigation of Cornerstone Therapeutics Inc.
PR Newswire - Tue Sep 17, 9:35AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cornerstone Therapeutics Inc. ("Cornerstone" or the "Company") (NASDAQ: CRTX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Chiesi Farmaceutici S.p.A. in a transaction valued at approximately $107 million.
Healthfirst Improves Member Retention Using Decision Point's "Micro Targeting" Technology
Business Wire - Tue Feb 25, 6:00AM CST
Decision Point Healthcare Solutions (Decision Point), an innovator in providing engagement analytics solutions to the health care industry, announced today that Healthfirst -- a not-for-profit managed care organization offering a variety of low- or no-cost health insurance programs to qualified individuals and families living in the New York metropolitan area -- was able to significantly improve Medicare member retention through its Decision Point-powered program to continually enhance its members' plan experience.
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Chiesi Farmaceutici Completes Acquisition of Cornerstone Therapeutics
PR Newswire - Tue Feb 04, 6:00AM CST
Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced that Chiesi has acquired all of the outstanding common shares of Cornerstone not already owned by Chiesi for $9.50 per share in cash. Prior to completing the transaction, Chiesi owned 58% of Cornerstone's outstanding shares.
Cornerstone Therapeutics Inc's stockholders votes in favour of merger with Chiesi Farmaceutici SpA at USD9.50 per share
M2 - Tue Feb 04, 4:38AM CST
Cornerstone Therapeutics Inc (NASDAQ:CRTX) stated on Monday that all of its outstanding common shares will be acquired for USD9.50 per share in cash under an approved merger agreement with Chiesi Farmaceutici SpA (Chiesi).
Cornerstone Therapeutics Inc. Stockholders Approve Merger
Marketwire - Mon Feb 03, 1:25PM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the "Company" or "Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, today announced that its stockholders have approved, at a special stockholder meeting held today, the previously announced merger agreement, under which Chiesi Farmaceutici S.p.A. ("Chiesi") will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash.
Cornerstone Therapeutics Adjourns Special Meeting of Stockholders
Marketwire - Fri Jan 31, 5:57PM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone") today announced that the special meeting of its stockholders scheduled to take place today has been adjourned. The special meeting will resume on February 3, 2014, at 1 p.m. EST at Cornerstone's offices located at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518. The purpose of the adjournment is to complete the solicitation of votes required for approval of a merger between Cornerstone and a subsidiary of Cornerstone's majority shareholder, Chiesi Farmaceutici S.p.A ("Chiesi").
Drugmaker Aptalis Files For IPO After Overhaul
at Investor's Business Daily - Thu Dec 26, 10:50AM CST
Drugmaker Aptalis Holdings filed to go public Thursday in an IPO expected to raise around half a billion dollars, as the company formerly traded as Axcan Pharma returns in a new incarnation. Private-equity firm TPG Capital acquired Axcan in 2007 and...
Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
Marketwire - Wed Nov 20, 7:02AM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today the launch of BETHKIS(R) (Tobramycin Inhalation Solution), a nebulized therapy indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.(1)
ACAD, CRTX, MACK and NVAX added to NASDAQ Healthcare Stock Watch List at EPR
ACCESSWIRE - Thu Nov 07, 8:28AM CST
New York, NY - (ACCESSWIRE) - 11/07/2013 - Equity Profile Report initiates its Health-care Stock Watch List adding ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), and Novavax, Inc. (NASDAQ:NVAX)
Cornerstone Therapeutics Reports Third Quarter 2013 Financial Results
Marketwire - Thu Nov 07, 6:01AM CST
Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call
Marketwire - Thu Oct 31, 4:01PM CDT
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, November 7, 2013, to discuss its financial results for the third quarter of 2013 ended September 30, 2013. Financial results are expected to be released before the open of the U.S. financial markets on Thursday, November 7, 2013.
Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
PR Newswire - Fri Oct 18, 1:25PM CDT
Securities lawyers at Deans & Lyons announced a class action against the board of Cornerstone Therapeutics Inc. (NASDAQ: CRTX) in connection with a buyout for $9.50 per share. Concerned CRTX investors should contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American Cystic Fibrosis Conference
Marketwire - Thu Oct 17, 8:02AM CDT
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) will exhibit at the North American Cystic Fibrosis Conference (NACFC), Oct. 17-19 at the Salt Palace Convention Center in Salt Lake City. The annual scientific meeting, sponsored by the Cystic Fibrosis Foundation, is designed for medical professionals focused on CF research and patient care.
Osiris Shares Continue to Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 15, 9:30AM CDT
Shares are up on the company's agreement for the sale of its culture-expanded mesenchymal stem cell business.
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Cornerstone Therapeutics, Inc. Buyout
Business Wire - Thu Sep 19, 2:44PM CDT
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Cornerstone Therapeutics, Inc.
Business Wire - Wed Sep 18, 8:00PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cornerstone Therapeutics, Inc. ("Cornerstone" or the "Company") (Nasdaq: CRTX) relating to the proposed acquisition by Chiesi Farmaceutici S.P.A. ("Chiesi").
Downgrade Alert for Cornerstone Therapeutics (CRTX)
Comtex SmarTrend(R) - Wed Sep 18, 7:11AM CDT
Cornerstone Therapeutics (NASDAQ:CRTX) was downgraded from Buy to Neutral at Ladenburg today. The stock closed yesterday at $9.40 on volume of 457,000 shares, above average daily volume of 83,000. Cornerstone Therapeutics share prices have moved between a 52-week high of $10.37 and a 52-week low of $4.56 and closed yesterday at 106% above that low price at $9.40 per share. Over the past week, the 200-day moving average (MA) has gone up 0.9% while the 50-day MA has advanced 0.9%.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by Board of Cornerstone Therapeutics, Inc. In Connection With Sale Of Company to Chiesi Farmaceutici SpA
PR Newswire - Tue Sep 17, 2:41PM CDT
Levi & Korsinsky is investigating the Board of Directors of Cornerstone Therapeutics, Inc. ("Cornerstone" or the "Company") (Nasdaq: CRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Chiesi Farmaceutici SpA ("Chiesi").
Ryan & Maniskas, LLP Announces Investigation of Cornerstone Therapeutics Inc.
PR Newswire - Tue Sep 17, 9:35AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cornerstone Therapeutics Inc. ("Cornerstone" or the "Company") (NASDAQ: CRTX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Chiesi Farmaceutici S.p.A. in a transaction valued at approximately $107 million.
(0)
(0)Quince Therapeutics, Inc. (QNCX) Stock Research Links
Scroll down for more posts ▼